Marketing authorization holders (MAHs) of ibuprofen-containing products in the European Union will have to update product information to include new warnings after reports of severe skin reactions association with use of the drug.
“Acute generalised exanthematous pustulosis (AGEP) has been reported with use of ibuprofen-containing products,” revealed the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?